RU2017134335A - Способ улучшения функции мочевого пузыря - Google Patents

Способ улучшения функции мочевого пузыря Download PDF

Info

Publication number
RU2017134335A
RU2017134335A RU2017134335A RU2017134335A RU2017134335A RU 2017134335 A RU2017134335 A RU 2017134335A RU 2017134335 A RU2017134335 A RU 2017134335A RU 2017134335 A RU2017134335 A RU 2017134335A RU 2017134335 A RU2017134335 A RU 2017134335A
Authority
RU
Russia
Prior art keywords
vitamin
composition
paragraphs
choline
subject
Prior art date
Application number
RU2017134335A
Other languages
English (en)
Other versions
RU2017134335A3 (ru
RU2715247C2 (ru
Inventor
ВИЛДЕ Маттеус Корнелис ДЕ
Original Assignee
Н.В. Нютрисиа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Н.В. Нютрисиа filed Critical Н.В. Нютрисиа
Publication of RU2017134335A publication Critical patent/RU2017134335A/ru
Publication of RU2017134335A3 publication Critical patent/RU2017134335A3/ru
Application granted granted Critical
Publication of RU2715247C2 publication Critical patent/RU2715247C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (34)

1. Применение (i) уридина и/или его эквивалента и (ii) n-3 полиненасыщенных жирных кислот (PUFA) для производства композиции для восстановления или улучшения функции мочевого пузыря у субъекта.
2. Применение по п. 1, где субъект является пациентом, который страдает, выздоравливает и/или страдал от неврологического нарушения, предпочтительно в результате повреждения спинного мозга.
3. Применение по п. 1 или 2, где n-3 PUFA выбирают из эйкозапентаеновой кислоты (EPA) и/или докозагексаеновой кислоты (DHA).
4. Применение по любому из предшествующих пунктов, где в сутки вводят 500-5000 мг DHA.
5. Применение по любому из предшествующих пунктов, где композиция дополнительно содержит холин и, предпочтительно, дополнительно содержит витамин(ы) группы B.
6. Применение по любому из предшествующих пунктов, где композиция дополнительно содержит фосфолипиды, холин, витамин(ы) группы B и антиоксиданты.
7. Применение по п. 5 или 6, где композиция содержит холин, витамин B6 и фолиевую кислоту.
8. Применение по любому из предшествующих пунктов, где уридин и/или его эквивалент представляет собой уридина монофосфат.
9. Применение по любому из предшествующих пунктов, где композиция содержит в 125 мл или в одной суточной дозе:
(i) 400-800 мг УМФ;
(ii) n-3 PUFA, включающие (a) 100-500 мг EPA и (b) 900-1500 мг DHA;
(iii) 50-600 мг фосфолипидов;
(iv) 200-600 мг холина;
(v) витамины группы B, включающие (a) 1-5 мкг витамина B12, (b) 0,5-3 мг витамина B6 и (c) 200-600 мкг фолиевой кислоты; и
(vi) антиоксиданты, включающие (a) 20-60 мг витамина E (альфа-TE), (b) 60-100 мг витамина C и (c) 40-80 мкг селена.
10. Применение по любому из предшествующих пунктов, где композиция представляет собой жидкость или твердое вещество, которое может быть восстановлено жидкостью.
11. Композиция для применения для восстановления или улучшения функции мочевого пузыря у субъекта, содержащая (i) уридин и/или его эквивалент и (ii) n-3 PUFA.
12. Композиция для применения по п. 11, где субъект является пациентом, который страдает, выздоравливает и/или страдал от неврологического нарушения, предпочтительно от повреждения спинного мозга.
13. Способ восстановления или улучшения функции мочевого пузыря у субъекта, включающий введение субъекту композиции, содержащей (i) уридин и/или его эквивалент и (ii) n-3 PUFA.
14. Способ по п. 13, где субъект является пациентом, который страдает, выздоравливает и/или страдал от неврологического нарушения, предпочтительно от повреждения спинного мозга.
15. Способ по п. 13 или 14, где n-3 PUFA выбирают из EPA и/или DHA.
16. Способ по любому из пп. 13-15, где в сутки вводят 500-5000 мг DHA.
17. Способ по любому из пп. 13-16, где композиция дополнительно содержит холин и, предпочтительно, дополнительно содержит витамин(ы) группы B.
18. Способ по любому из пп. 13-17, где композиция дополнительно содержит фосфолипиды, холин, витамин(ы) группы B и антиоксиданты.
19. Способ по п. 17 или 18, где композиция содержит холин, витамин B6 и фолиевую кислоту.
20. Способ по любому из пп. 13-19, где уридин и/или его эквивалент представляет собой уридина монофосфат.
21. Способ по любому из пп. 13-20, где композиция содержит в 125 мл или в одной суточной дозе:
(i) 400-800 мг УМФ;
(ii) n-3 PUFA, включающие (a) 100-500 мг EPA и (b) 900-1500 мг DHA;
(iii) 50-600 мг фосфолипидов;
(iv) 200-600 мг холина;
(v) витамины группы B, включающие (a) 1-5 мкг витамина B12, (b) 0,5-3 мг витамина B6 и (c) 200-600 мкг фолиевой кислоты; и
(vi) антиоксиданты, включающие (a) 20-60 мг витамина E (альфа-TE), (b) 60-100 мг витамина C и (c) 40-80 мкг селена.
22. Способ по любому из пп. 13-21, где композиция представляет собой жидкость или твердое вещество, которое может быть восстановлено в жидкости.
RU2017134335A 2015-03-16 2016-03-15 Способ улучшения функции мочевого пузыря RU2715247C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NLPCT/NL2015/050168 2015-03-16
PCT/NL2015/050168 WO2016148561A1 (en) 2015-03-16 2015-03-16 Method for improving bladder function
PCT/NL2016/050184 WO2016148568A1 (en) 2015-03-16 2016-03-15 Method for improving bladder function

Publications (3)

Publication Number Publication Date
RU2017134335A true RU2017134335A (ru) 2019-04-03
RU2017134335A3 RU2017134335A3 (ru) 2019-09-18
RU2715247C2 RU2715247C2 (ru) 2020-02-26

Family

ID=52829270

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017134335A RU2715247C2 (ru) 2015-03-16 2016-03-15 Способ улучшения функции мочевого пузыря

Country Status (12)

Country Link
US (1) US20180110794A1 (ru)
EP (1) EP3270905A1 (ru)
JP (1) JP2018508548A (ru)
KR (1) KR20170138434A (ru)
CN (1) CN107635551A (ru)
AU (1) AU2016233980A1 (ru)
BR (1) BR112017019838A2 (ru)
CA (1) CA2979979A1 (ru)
MX (1) MX2017011994A (ru)
RU (1) RU2715247C2 (ru)
SG (1) SG11201707591YA (ru)
WO (2) WO2016148561A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220005024A (ko) * 2019-05-06 2022-01-12 페레르 인터내쇼날 에스.에이. 피리미딘 및/또는 퓨린 유도체 및 b 비타민을 포함하는 다층 약제학적 또는 기능 식품용 고체 투여 형태, 이의 제조 및 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30853A (en) * 1860-12-04 Machine fob
US8518882B2 (en) 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
WO2012125020A1 (en) 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
WO2013066152A1 (en) 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
WO2013066151A1 (en) 2011-10-31 2013-05-10 N.V. Nutricia Improving recognition

Also Published As

Publication number Publication date
CA2979979A1 (en) 2016-09-22
EP3270905A1 (en) 2018-01-24
MX2017011994A (es) 2018-08-23
US20180110794A1 (en) 2018-04-26
AU2016233980A1 (en) 2017-10-19
BR112017019838A2 (pt) 2018-06-05
SG11201707591YA (en) 2017-10-30
CN107635551A (zh) 2018-01-26
WO2016148568A1 (en) 2016-09-22
KR20170138434A (ko) 2017-12-15
WO2016148561A1 (en) 2016-09-22
RU2017134335A3 (ru) 2019-09-18
JP2018508548A (ja) 2018-03-29
RU2715247C2 (ru) 2020-02-26

Similar Documents

Publication Publication Date Title
JP2796838B2 (ja) 精神分裂症および／または関連した晩発性運動障害の治療のための薬剤を製造する方法
RU2014121891A (ru) Улучшение узнавания
RU2013145701A (ru) Способ лечения нейротравмы
WO2008147562A3 (en) Dietary formulations and methods for treatment of inflammation and other disorders
US11318150B1 (en) Vitamin supplement compositions with enhanced bioavailability
US20110223246A1 (en) Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
JP6092843B2 (ja) 神経障害の治療用組成物
RU2014139834A (ru) Способ улучшения функциональной синаптической связи
US8889633B2 (en) Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
HRP20150767T1 (hr) Pripravak koristan za lijeäśenje poremeä†aja metabolizma lipida
US10039765B1 (en) Vitamin supplement compositions with enhanced bioavailability
EP2272383A1 (en) Composition Comprising Omega-7 and/or Omega-4 Fatty Acids
US20090099261A1 (en) Omega-3 mixtures
US9962355B2 (en) Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies
CA2073913A1 (en) Preparation of fatty acid medicaments
US10675292B2 (en) Method for reducing white matter lesions, white matter hyperintensities (WMH), leukoaraiosis or periventricular white matter disease in elderly
DE202015009883U1 (de) Eicosapentaensäurealkylester enthaltende Zusammensetzung
US20110217275A1 (en) Compositions comprising probiotic bacteria of the strain bacillus coagulans and omega-3 polyunsaturated fatty acids or derivatives thereof
Asadi-Shekaari et al. Maternal feeding with walnuts (Juglans regia) improves learning and memory in their adult pups
FI125743B (fi) Rasvakoostumus iho-ongelmien ehkäisyyn tai hoitoon
RU2017134335A (ru) Способ улучшения функции мочевого пузыря
US20140256813A1 (en) Methods for the treatment of brain injury using omega-3 fatty acids
JP2007217311A (ja) 神経細胞分化誘導剤
Prabhakar et al. Fatty acid composition of Sargassum wightii and Amphiroa anceps collected from the Mandapam coast Tamil Nadu, India
FI3634396T3 (fi) Koostumus L-DOPA-hoidon tehon parantamiseen

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20210316